EGFR and adenocarcinoma: Twenty (46%) of the 43 adenocarcinoma cases were positive for multiple RTKs, including 7 cases (16%) with EGFR+/HER2+/c-Met+, 4 cases (9%) with EGFR+/HER2+/c-Met-, 3 cases (7%) with EGFR+/HER2-/c-Met+, and 6 cases (14%) with EGFR-/HER2+/c-Met+.